Age related changes in pancreatic beta cells: A putative extra-cerebral site of Alzheimer’s pathology

Magdalena Maj, Aysegul Ilhan, Dashurie Neziri, Wolfgang Gartner, Tord Berggard, Johannes Attems, Wolfgang Base, Ludwig Wagner

INTRODUCTION

Prevalence of impaired glucose tolerance and type 2 diabetes mellitus (T2DM) is increasing among the elderly in humans. The absolute number of T2DM patients is rising worldwide, particularly in industrialized countries. This is not only because of the higher incidence of obesity and reduced physical exercise, but is also due to the longer life expectancy in these countries, as well as superior food quality, and the availability of highly effective medication. However, a longer life span brings with it age-associated

Abstract

Frequent concomitant manifestation of type 2 diabetes mellitus (T2DM) and Alzheimer’s disease (AD) has been recently demonstrated by epidemiological studies. This might be due to functional similarities between β-cells and neurons, such as secretion on demand of highly specific molecules in a tightly controlled fashion. An additional similarity represents the age-related alteration of hyperphosphorylated tau in AD patients. Similarly, alterations have been identified in β-cells of T2DM patients. The islet amyloid polypeptide has been associated with β-cell apoptosis. As a consequence of increasing age, the accumulation of highly modified proteins together with decreased regenerative potential might lead to increasing rates of apoptosis. Moreover, reduction of β-cell replication capabilities results in reduction of β-cell mass in mammals, simultaneously with impaired glucose tolerance. The new challenge is to learn much more about age-related protein modifications. This can lead to new treatment strategies for reducing the incidence of T2DM and AD.

Key words: Type 2 diabetes mellitus; Pancreatic beta cells; Age; Alzheimer’s disease; Hyperphosphorylated tau; Islet amyloid polypeptide

Peer reviewers: Moshira Abdel Hakim Rateb, MD, Assistant Professor of Human Physiology, Faculty of Medicine (Kasr Al Aini.), Manial El Roda, Cairo University, Cairo, Egypt

Maj M, Ilhan A, Neziri D, Gartner W, Berggard T, Attems J, Base W, Wagner L. Age related changes in pancreatic beta cells: A putative extra-cerebral site of Alzheimer’s pathology. World J Diabetes 2011; 2(4): 49-53 Available from: URL: http://www.wjgnet.com/1948-9358/full/v2/i4/49.htm DOI: http://dx.doi.org/10.4239/wjd.v2.i4.49
diseases such as diabetes mellitus type 2, cognitive disorders, and Alzheimer’s disease (AD). Primarily, one would not expect that these two very different forms of age related complications (T2DM and AD) to have any connection. Yet, epidemiological studies have demonstrated that, when compared with age matched individuals with absence of cognitive dysfunction\(^{[2,3]}\), impaired glucose tolerance and T2DM is more prevalent among AD patients. The link between these entities with different loci of pathological processes might be found in similar key mediators or signaling pathways. In both, the pancreatic beta cell and neurons of the central nervous system, secretion on demand of highly specific molecules represents a genuine task. This is mediated \(\text{via a tightly controlled exocytosis process. The SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein receptor) protein complex gears transmitter and insulin secretion at neurons and beta cells, respectively. The SNARE complex exerts its function at the neuronal synapse and in the }\beta\text{-cell, using already pre-primed mature granules. Three so called SNARE proteins participate in fusing the vesicles to the plasma membrane: the vesicle-associated membrane protein (VAMP, also called synaptobrevin); syntaxin, an integral plasma membrane protein; and the synaptosomal-associated protein of 25 kDa (SNAP-25), anchored to the plasma membrane \(\text{via a palmitoyl group. Together, these three proteins form a helical bundle consisting of four amphipathic helices, or SNARE motifs, two of which are contributed by SNAP-25}^{[5]}\). It is believed that assembly of the SNARE complex proceeds in a zipper-like fashion from the \(\text{N-terminal end of the interacting helices toward the C-terminal membrane anchors. In this way, assembly of the proteins in the opposing membranes pulls the membranes together}^{[4]}\). At the beginning of membrane fusion, the SNARE proteins are located in still separated membranes (so-called \text{trans-complexes}) and, after fusion, the trans-membrane segments of the SNAREs are present in the same membrane (\text{cis-complexes}). To restore the cell for new exocytosis events, the \text{cis-complexes} are then disassembled by NSF (N-ethylmaleimide-sensitive factor) and additional cofactors\(^{[3]}\), and vesicles containing VAMP are recycled. Secretogogin, a novel hexa EF-hand calcium-binding protein was recently found to interact with SNAP-25\(^{[6]}\). Further complex interdependencies will be demonstrated in establishing inter-acts\(^{[7]}\).

**ALZHEIMER’S PATHOLOGY IN PANCREATIC }\beta\text{-CELLS}

As most cellular processes are regulated by multi-protein complexes, abolishing or enhancing a protein-protein interaction may have a profound impact and possibly manifests in distinct diseases. Since protein-protein interactions are critical events for a wide range of physiological and pathological processes, the precise control of these interactions and their biological consequences present a major challenge and opportunity for modern drug design.\(^{[8]}\). Hyperphosphorylation and glycosylation might induce impairment of the protein interaction machinery. As protein expression deficiencies of SNARE members have been demonstrated in the brain at the Lewy body variant of AD patients\(^{[9]}\), there might exist forms of T2DM in which pancreatic }\beta\text{-cells undergo similar expression deficiencies, but this is still a matter of investigation.

In contrast to neuronal transmitters, insulin does not undergo a reuptake into }\beta\text{-cells. The premature insulin granules\(^{[10]}\) have to be transported to the cell periphery along microtubules \(\text{via an energy-consuming process using kinesin}^{[11]}\). In this respect, microtubular dynamics as well as microtubule-associated protein tau (MAPT), also named tau, play an important role. Abnormalities in tau protein structure such as tangles and hyperphosphorylated tau aggregates were identified in the brains of AD patients\(^{[12,13]}\) about 30 years ago. This has led to the technical term tauopathy and has been defined as detergent insoluble tau aggregates forming tangles and neuritic plaques\(^{[14]}\). Very recently, hyperphosphorylated tau, representing a factor responsible for the inhibition of microtubule assembly and microtubule disruption\(^{[15]}\), has been identified in pancreatic islets of Langertans of T2DM patients\(^{[16]}\). In contrast, this was not found in pancreatic islets of healthy individuals. Such data have been confirmed by in vitro studies using insulinoma tissue and cell lines from rodents\(^{[17]}\). At least six individual tau isoforms have been identified in these rodent }\beta\text{-cell lines, of which two are of higher molecular weight than the brain derived isoforms. Insoluble aggregates were isolated and demonstrated. Most interestingly, a slight but not significant up-regulation of tau\(^{[18]}\) expression could be defined at the gene level using expression screens when comparing normal age matched donor islets with pancreatic islets from T2DM patients.

Although tau has become an important molecule in defining AD pathology, it is not solely responsible for disease development\(^{[19]}\). In the brain, extracellular beta amyloid deposits are the second main hallmark of AD pathology. Interestingly, a homologous protein\(^{[20]}\) named islet amyloid polypeptide (IAPP)\(^{[21]}\) is present in beta cells, which is intriguing in this respect. It is co-expressed and secreted with insulin by pancreatic beta cells\(^{[22,23]}\). The IAPP has a propensity to misfold and aggregate into cytotoxic oligomers, which result in islet amyloid deposits found in T2DM patients\(^{[24]}\). Oligomers of human IAPP are known to cause membrane disruption\(^{[25]}\), and are therefore involved in the mediation of }\beta\text{-cell apoptosis in T2DM. Interestingly, the single amino acid mutation (proline substitution) in rodent IAPP hinders the formation of IAPP deposits\(^{[26]}\), and rodents do not spontaneously develop diabetes characterized by islet amyloid deposits\(^{[24]}\). This, in turn, has led to the development of transgenic rats expressing the human variant of IAPP\(^{[27]}\). The transgenic rat model indeed resembles the T2DM of humans closely, and provides proof that this molecule is involved in derangement of }\beta\text{-cell function. It is of note that, using these models, it has been shown that the toxic effect of human IAPP on }\beta\text{-cell apoptosis is initiated by a threshold-dependent effect}^{[25]}\).
MODIFICATIONS OF INSULIN SECRETION

Insulin secretion from pancreatic beta cells has been monitored in a pulsatile mode under physiological conditions[25,45,49,50]. The frequency of pulses changes depending on the blood glucose level, and can be influenced by drugs such as sulfonylureas[29]. Most interestingly, impairment of this mode of secretion has been observed much earlier than the abnormal glucose tolerance could be measured[29]. Each pulse of insulin release is preceded by an increase of intracellular calcium[29]. This tightly controlled mechanism is reviewed by Tengholm and Gylfe[31] and is derailed in individuals with impaired glucose tolerance and diabetes[32,33]. Additionally, an age-dependent change in pulsatile insulin secretion has been demonstrated in animal models[38,39] as well as in humans[40].

β-CELL REPLICATION AND AGE

It has been demonstrated in rodent models that the beta cell mass is the result of a balanced mode of replication and apoptosis[16,37]. An adjusted increase in replication has been found in obesity of rodents[29] and humans[39]. Moreover, the adaptive increase in beta cell mass has been shown to have important biological relevance for the increased insulin demand in pregnancy[40,41,44]. Furthermore, as depicted in rats, these adaptations are necessary to balance the age-related insulin resistance building up within 12 mo of birth[44]. Data beyond this age are not available from rats, though it has to be speculated that this β-cell replicative potential decreases in rodents in an age-dependent manner[43] as it has been shown for humans[44]. In younger individuals, β-cell mass can adapt to increase in body mass in order to maintain glucose tolerance within the normal range, this seems not to be the case in older individuals.

β-CELL APOPTOSIS AND AGE

Although T2DM has been associated with increased β-cell apoptosis[29,45,46], it does not necessarily mean that there is an increase in apoptosis going along with the age. However, there exists clear evidence that islet amyloid polypeptide increases with age at the islet of Langerhans[11,46]. This physiological peptide can cause apoptosis in its oligomeric form[24,45,49,40]. In addition to this, hyperphosphorylated tau protein can accumulate within the islet of Langerhans, as mentioned above[41]. Rodent models suggest that increased apoptosis might be responsible for the decrease in β-cell mass[26,27,31,39].

PROTECTIVE EFFECTS

It has been suggested that several protective effects exist to prevent neuronal death[13,34]. The former author describes that the calcium-binding protein secretagogin might exhibit a neuro-protective effect. This protein is highly expressed at the pancreatic islet of Langerhans, and might indeed exert important sensing capabilities at the calcium spikes preceding each pulse of insulin secretion[55]. Some preliminary data have been suggested in recent work, which might indicate that this protein provides more resistance to β-cell stressors under in vitro conditions[57]. Similarly, chaperon proteins have been implicated in refolding proteins back into their normal structure, following derangement from their native structure due to exposure to toxins or disease-mediated changes in body temperature[16,37].

Further basic research work will be necessary to teach us how age-related changes in β-cells can be reduced, prevented and counteracted.

REFERENCES

1. Janson J, Laedtke T, Parisi JE, O’Brien P, Petersen RC, Butler PC. Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 2004; 53: 474-481
2. Ristow M. Neurodegenerative disorders associated with diabetes mellitus. J Mol Med 2004; 82: 510-529
3. Sutton RB, Fasthauer D, Jahn R, Brunger AT. Crystal structure of a SNARE complex involved in synaptic exocytosis at 2.4 A resolution. Nature 1998; 395: 347-353
4. Lin RC, Scheller RH. Structural organization of the synaptic exocytosis core complex. Neuron 1997; 19: 1087-1094
5. Sollier N, Bennett MK, Whiteheart SW, Scheller RH, Rothman JE. A protein assembly-disassembly pathway in vitro that may correspond to sequential steps of synaptic vesicle docking, activation, and fusion. Cell 1993; 75: 409-418
6. Rogstam A, Linse S, Lindqvist A, James P, Wagner L, Berggard T. Binding of calcium ions and SNAP-25 to the hex-FH-end protein secretagogin. Biochem J 2007; 401: 353-363
7. Bauer MC, O’Connel DJ, Maj M, Wagner L, Cahill DJ, Linse S. Identification of a high-affinity network of secretagoginin-binding proteins involved in vesicle secretion. Molecular BioSystems, in process
8. Toogood PL. Inhibition of protein-protein association by small molecules: approaches and progress. J Med Chem 2002; 45: 1543-1558
9. Mukaetova-Ladinska EB, Xuereb JH, Garcia-Sierra F, Hurt J, Gertz HJ, Hills R, Brayne C, Huppert FA, Paykel ES, McGee MA, Jakes R, Hiner WG, Harrington CR, Wischik CM. Lewy body variant of Alzheimer’s disease: selective neocortical loss of t-SNARE proteins and loss of MAP2 and alpha-synuclein in medial temporal lobe. Nature 2000; 75: 1463-1475
10. Orci L, Ravazzola M, Amherdt M, Madsen O, Vassalli JD, Perrelet A. Direct identification of prohormone conversion site in insulin-secreting cells. Cell 1985; 42: 671-681
11. Varadi A, Tsuiboi T, Johnson-Cadwell LI, Allan VJ, Rutter GA. Kinesin I and cytoplasmic dynein orchestrate glucose-stimulated insulin-containing vesicle movements in clonal MIN6 beta-cells. Biochim Biophys Acta 2003; 1615: 272-282
12. Grundke-Iqbal I, Iqbal K, Quinlan M, Tung YC, Zaidi MS, Wisniewski HM. Microtubule-associated protein tau. A component of Alzheimer’s paired helical filaments. J Biol Chem 1986; 261: 6084-6089
13. Ihara Y, Nukina N, Miura R, Ogawara M. Phosphorylated tau protein is integrated into paired helical filaments in Alzheimer’s disease. J Biochem 1986; 99: 1807-1810
14. Buee L, Bussiere T, Buee-Scherrer V, Delacourte A, Hof PR. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev 2000; 33: 95-130
15. Alonso Adel C, Li B, Grundke-Iqbal I, Iqbal K. Polymerization of hyperphosphorylated tau into filaments eliminates its inhibitory activity. Proc Natl Acad Sci USA 2006; 103: 8864-8869
16. Miklossy J, Qing H, Radenovic A, Kis A, Vileno B, Laszlo F, Miller L, Martins RN, Waeber G, Moore V, Bosman F, Khalili
K, Darbinian N, McGeer PL. Beta amyloid and hyperphosphorylated tau deposits in the pancreas in type 2 diabetes. *Neurobiol Aging* 2010; 31: 1503-1515

17 Maj M, Gartner W, Ilhaan A, Neufeld D, Attems J, Wagner L. Expression of tau in insulin-secreting cells and its interaction with the calcium-binding protein secretagogin. *J Endocrinol* 2010; 205: 25-36

18 Gunton JE, Kulkarni RN, Yim S, Okada T, Hawthorne WJ, Tseng YH, Roberson RS, Ricordi C, O’Connell PJ, Gonzalez FJ, Kahn CR. Loss of ARNT/HIF1beta mediates altered gene expression and pancreatic-leaf dysfunction in human type 2 diabetes. *Cell Metab* 2005; 12: 337-349

19 Querfurth HW, LaFerla FM. Alzheimer’s disease. *Nat Rev Genet* 2010; 12: 329-344

20 Yan LM, Velkova A, Tatarsek-Nossol M, Andreetto E, Kapurioti A. IAPP mimic blocks Abeta cytoskeletal self-assemble: cross-suspension of amyloid toxicity of Abeta and IAPP suggest a molecular link between Alzheimer’s disease and type II diabetes. *Angeu Chem Int Ed Engl* 2007; 46: 1246-1252

21 Cooper GJ, Willis AC, Clark A, Turner RC, Sim RB, Reid KB. Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. *Proc Natl Acad Sci USA* 1987; 84: 8626-8632

22 Gurlo T, Ryazantsev S, Huang CJ, Yeh MW, Reber HA, Hines OJ, O’Brien TD, Glabe CG, Butler PC. Evidence for proteotoxicity in beta cells in type 2 diabetes: toxic islet amyloid polypeptide oligomers form intracellularly in the secretory pathway. *Am J Pathol* 2010; 176: 861-869

23 Young AA, Gedulin B, Wolfe-Lopez D, Groene HF, Rink TJ, Cooper GJ, Amylin and insulin in rat soleus muscle: dose responses for cosecreted noncompetitive antagonists. *Am J Physiol* 1992; 263: E274-E281

24 Kahn SE, Andrikopoulos S, Verchere CB. Islet amyloid: a long-recognized but underappreciated pathological feature of type 2 diabetes. *Diabetes* 1999; 48: 241-253

25 Ritzel RA, Meier JJ, Lin CY, Veldhuis JD, Butler PC. Human islet amyloid polypeptide oligomers disrupt cell coupling, induce apoptosis, and impair insulin secretion in isolated human islets. *Diabetes* 2007; 56: 65-71

26 Matveyenkov AV, Butler PC. Islet amyloid polypeptide (IAPP) transgenic rodents as models for type 2 diabetes. *ILAR J* 2006; 47: 225-233

27 Butler AE, Jang J, Gurlo T, Carty MD, Soeller WC, Butler PC. Diabetes due to a progressive defect in beta-cell mass in rats transgenic for human islet amyloid polypeptide (HIP Rat): a new model for type 2 diabetes. *Diabetes* 2004; 53: 1509-1516

28 Bergsten P. Glucose-induced pulsatile insulin release from single islets at stable and oscillatory cytoplasmic Ca\(^{2+}\). *Am J Physiol* 1998; 274: E796-E800

29 Gilon P, Shepherd RM, Henquin JC. Oscillations of secretion driven by oscillations of cytoplasmic Ca\(^{2+}\) as evidence in single pancreatic islets. *J Biol Chem* 1993; 268: 22265-22268

30 Schmitt O, Forksen N, Nyhholm B, Skaerbaek C, Butler PC, Veldhuis JD, Pincus SM. Disorderly and nonstationary insulin secretion in relatives of patients with NIDDM. *Am J Physiol* 1997; 272: E218-E226

31 Tengholm A, Gylee E. Oscillatory control of insulin secretion. *Mol Cell Endocrinol* 2009; 297: 58-72

32 Lang DA, Matthews DR, Burnett M, Turner RC. Brief, irregular oscillations of basal plasma insulin and glucose concentrations in diabetic man. *Diabetes* 1981; 30: 435-439

33 O’Rahilly S, Turner RC, Matthews DR. Impaired pulsatile secretion of insulin in relatives of patients with non-insulin-dependent diabetes. *N Engl J Med* 1988; 318: 1225-1230

34 Matveyenkov AV, Veldhuis JD, Butler PC. Adaptations in pulsatile insulin secretion, hepatic insulin clearance, and beta-cell mass to age-related insulin resistance in rats. *Am J Physiol Endocrinol Metab* 2008; 295: 1532-E841

35 Ihm SH, Matsumoto I, Sawada T, Nakano M, Zhang HJ, Ansie JD, Sutherland DE, Hering BJ. Effect of donor age on function of isolated human islets. *Diabetes* 2006; 55: 1361-1368

36 Finegood DT, Scaglia L, Bonner-Weir S. Dynamics of beta-cell mass in the growing rat pancreas. Estimation with a simple mathematical model. *Diabetes* 1995; 44: 249-256

37 Lee YC, Nielsen H. Regulation of beta cell replication. *Mol Cell Endocrinol* 2009; 297: 18-27

38 Flier SN, Kulkarni RN, Kahn CR. Evidence for a circulating islet cell growth factor in insulin-resistant states. *Proc Natl Acad Sci USA* 2001; 98: 7475-7480

39 Flatt PR, Green BD. Nutrient regulation of pancreatic beta-cell function in diabetes: problems and potential solutions. *Biochim Biophys Acta* 2008; 1787: 7-28

40 Kornik SK, Chen H, McLean GW, Heit JJ, Gu X, Zhang Y, Fontaine A, Yen MH, Kim SK. Menin controls growth of pancreatic beta-cells in pregnant mice and promotes gestational diabetes mellitus. *Science* 2007; 318: 806-809

41 Parsons JA, Brelje TC, Sorenson RL. Adaptation of islets of Langerhans to pregnancy: increased islet cell proliferation and insulin secretion correlates with the onset of placental lactogen secretion. *Endocrinology* 1992; 130: 1439-1446

42 Van Assche FA, Aerts L, De Prins F. A morphological study of the endocrine pancreas in human pregnancy. *Br J Obstet Gynaecol* 1978; 85: 818-820

43 Perfetti R, Wang Y, Shuldiner AR, Egan JM. Molecular investigation of age-related changes in mouse endocrine pancreas. *J Gerontol A Biol Sci Med Sci* 1996; 51: B331-B336

44 Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. *Diabetes* 2003; 52: 102-110

45 Meier JJ, Kayed R, Lin CY, Gurlo T, Haataja L,Jayasinge S, Langen R, Glabe CG, Butler PC. Inhibition of human IAPP fibril formation does not prevent beta-cell death: evidence for distinct actions of oligomers and fibrils of human IAPP. *Am J Physiol Endocrinol Metab* 2006; 291: E1317-E1324

46 Rhodes CJ. Type 2 diabetes—a matter of beta-cell life and death? *Science* 2005; 307: 380-384

47 Leckström A, Lundqvist I, Ma Z, Westmark P. Islet amyloid polypeptide and insulin relationship in a longitudinal study of the genetically obese (ob/ob) mouse. *Pancera* 1999; 18: 266-273

48 Takada K, Kanatsuka A, Tomoyama Y, Yagui K, Nishimura M, Saito Y, Makino H. Islet amyloid polypeptide/amylin contents in pancreas change with increasing age in genetically obese and diabetic mice. *Diabetes Res Clin Pract* 1996; 35: 153-158

49 Haataja L, Gurlo T, Huang CJ, Butler PC. Islet amyloid in type 2 diabetes: the toxic oligomer hypothesis. *Endocr Rev* 2008; 29: 303-316

50 Lorenzo A, Razzaboni B, Weir GC, Yankner BA. Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus. *Nature* 1994; 368: 756-760

51 Butler AE, Janson J, Soeller WC, Butler PC. Increased beta-cell apoptosis prevents adaptive increase in beta-cell mass in mouse model of type 2 diabetes: evidence for role of islet amyloid formation rather than direct action of amyloid. *Diabetes* 2003; 52: 2304-2314

52 Stefan M, Simmons RA, Bertera S, Trucco MM, Eski F, Drain P, Nicholls RD. Global deficits in development, function, and gene expression in the endocrine pancreas in a deletion mouse model of Prader-Willi syndrome. *Am J Physiol Endocrinol Metab* 2011; epub ahead of print

53 Attems J, Preusser M, Gросinger-Quass M, Wagner L, Lintner F, Jellinger K. Calcium binding protein secretagogin-expressing neurons in the human hippocampus are largely resistant to neurodegeneration in Alzheimer’s disease. *Neuropathol Appl Neurobiol* 2008; 34: 23-32

54 Attems J, Quass M, Gartner W, Nabokikh A, Wagner L, Steurer S, Arbe S, Lintner F, Jellinger K. Immuneactivity of calcium binding protein secretagogin in the human hippocampus is restricted to pyramidal neurons. *Exp Gerontol* 2007; 42: 215-222
Maj M et al. Age related changes in pancreatic beta cells

55 Wagner L, Oliyarnyk O, Gartner W, Nowotny P, Groeger M, Kaserer K, Waldhaeusl W, Pasternack MS. Cloning and expression of secretagogin, a novel neuroendocrine- and pancreatic islet of Langerhans-specific Ca\textsuperscript{2+}-binding protein. *J Biol Chem* 2000; 275: 24740-24751

56 Vabulas RM, Raychaudhuri S, Hayer-Hartl M, Hartl FU. Protein folding in the cytoplasm and the heat shock response. *Cold Spring Harb Perspect Biol* 2010; 2: a004390

57 Zhang H, Xu LQ, Perrett S. Studying the effects of chaperones on amyloid fibril formation. *Methods* 2011; 53: 285-294

S- Editor Zhang HN  L- Editor Herholdt A  E- Editor Zhang L